Swedish biotech company Cantargia has announced an agreement to sell all assets related to its CAN10 immunology program to Japanese healthcare giant Otsuka Pharmaceutical. Cantargia will receive an upfront cash payment of USD 33 million and is eligible for up to an additional USD 580 million in milestone payments, as well as earn-out payments from global product sales. The announcement was met with a strong market reaction, as Cantargia’s share price surged by over 250 percent on the day of the news.
– Our deal with Otsuka is a clear demonstration of the growing interest and importance in developing new therapies in this area, says Damian Marron, Interim CEO.
Read the article at biostock.se:
https://biostock.se/en/2025/07/otsuka-pharmaceutical-acquires-cantargias-can10-program-in-a-deal-worth-over-usd-600-million/